Skip to main content
. 2023 Aug 28;3(8):1672–1677. doi: 10.1158/2767-9764.CRC-23-0230

TABLE 2.

Objective responses in the expansion cohort

Overall
(N = 30)
Objective response
 CR 2.00 (6.7%)
 PR 15.0 (50.0%)
 SD 9.00 (30.0%)
 PD 3.00 (10.0%)
 NE 1.00 (3.3%)

Abbreviations: PD, progressive disease; NE, non-evaluable.